Incyte’s portfolio increased from 17 to 16 clinical compounds and from 20 to 19 approved products, while newly acquired VIVID Phase 3 clinical trials remained listed.

{
  "signal_id": "3013036f-cb8a-55cc-840b-4b12f48b22a0",
  "signal_type": "website-intelligence",
  "signal_subtype": "productExpansion",
  "detected_at": "2026-08-17T00:00:00+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "summary": "Incyte’s portfolio increased from 17 to 16 clinical compounds and from 20 to 19 approved products, while newly acquired VIVID Phase 3 clinical trials remained listed.",
    "evidence": "The portfolio changed from “17 Clinical Compounds” and “20 Approved Products” to “16 Clinical Compounds” and “19 Approved Products”; the page continues to identify VGA039 as the VIVID Phase 3 Von Willebrand Disease program.",
    "relevance": 0.71,
    "source_url": "https://www.incyte.com/what-we-do/pharmaceutical-portfolio",
    "impact_rationale": "The portfolio count change indicates ongoing portfolio growth and clinical-program activity, although the simultaneous reduction in approved products suggests portfolio turnover rather than a net increase."
  }
}

curl https://signals.autobound.ai/v1/signals/3013036f-cb8a-55cc-840b-4b12f48b22a0 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"incyte.com","limit":20}'